Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Brazil Bulgaria Canada Chile China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania Slovakia South Africa South Korea Spain Taiwan Thailand United States View all |
NCT06133972 |
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS |
Atypical Hemolytic Uremic Syndrome | Phase3 | Brazil China Czechia India Japan Turkey (Türkiye) View all |
NCT05795140 |
Kesimpta (Ofatumumab) Pregnancy Registry |
Multiple Sclerosis, Pregnancy | United States | NCT05634967 | |
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors |
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors | United States | NCT05868629 | |
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers |
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer | Phase1 | Belgium Canada France Germany Israel Italy Netherlands Spain Switzerland United States View all |
NCT06562192 |
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study |
Sickle Cell Disease | Phase4 | Colombia Lebanon Oman United States View all |
NCT04657822 |
Asciminib Roll-over Study |
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase4 | Argentina Austria Bulgaria Canada China Czechia France Germany Italy Malaysia Mexico Oman Poland Portugal Russia South Korea Spain Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT04877522 |
Asciminib RMP Study |
Chronic Myeloid Leukemia | South Korea | NCT05943522 | |
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea |
Non-Small-Cell Lung Carcinoma | South Korea | NCT05703516 | |
CAR-T Long Term Follow Up (LTFU) Study |
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Phase3 | Australia Austria Belgium Canada China Denmark Finland France Germany Greece Hong Kong Israel Italy Japan Norway Saudi Arabia Singapore South Korea Spain Taiwan United Kingdom United States View all |
NCT02445222 |